Published in AIDS on April 14, 2000
Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. J Int AIDS Soc (2009) 1.37
Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol (2003) 0.98
Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol (2005) 0.97
Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates. Eur J Clin Microbiol Infect Dis (2006) 0.84
Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J Clin Microbiol (2002) 0.83
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (1999) 4.39
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol (1997) 4.08
Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol (1998) 3.77
Undergraduate research. Genomics Education Partnership. Science (2008) 3.45
Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. J Viral Hepat (2009) 3.02
Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis (1995) 2.89
Impacts of atmospheric anthropogenic nitrogen on the open ocean. Science (2008) 2.85
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
[CD4+ lymphocytes and opportunistic infections and neoplasms in patients with human immunodeficiency virus infection]. Med Clin (Barc) (1994) 2.56
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet (2004) 2.33
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health (2002) 2.13
The membrane transport factor TAP/p115 cycles between the Golgi and earlier secretory compartments and contains distinct domains required for its localization and function. J Cell Biol (1998) 2.05
[Malignant fibrous histiocytoma of soft tissue: description of 10 cases]. Med Clin (Barc) (1991) 2.02
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS (1999) 2.00
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
[Treatment and prophylaxis of the principal infections associated with the human immunodeficiency virus]. Med Clin (Barc) (1993) 1.96
[Prevalence of antibodies against hepatitis C virus in a sample of homosexual males]. Med Clin (Barc) (1993) 1.94
Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax (2004) 1.93
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS (2001) 1.90
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr (1999) 1.88
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med (2008) 1.84
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.83
Lipids, lipoproteins, and apoproteins in serum during infection. Clin Chem (1986) 1.82
Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review. Clin Infect Dis (1994) 1.82
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81
Tuning the conductance of single-walled carbon nanotubes by ion irradiation in the Anderson localization regime. Nat Mater (2005) 1.70
Compartment syndrome in experimental chronic obstructive pancreatitis: effect of decompressing the main pancreatic duct. Br J Surg (1994) 1.69
Risk factors associated with human cystic echinococcosis in Florida, Uruguay: results of a mass screening study using ultrasound and serology. Am J Trop Med Hyg (1998) 1.68
Transient uptake and storage of serotonin in developing thalamic neurons. Neuron (1996) 1.67
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS (2000) 1.67
[Pacemaker implantation in a patient with persistent left superior vena cava and atresia of the right superior vena cava]. Rev Port Cardiol (1994) 1.66
Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol (2000) 1.59
Introduction of HIV drug-resistance testing in clinical practice. AIDS (1999) 1.58
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology (2000) 1.56
Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS (2001) 1.56
Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol (1998) 1.54
Heat requirement for the onset of the Olea europaea L. pollen season in several sites in Andalusia and the effect of the expected future climate change. Int J Biometeorol (2004) 1.54
Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer (2002) 1.51
Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci (2007) 1.50
Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect (1990) 1.50
Evidence for production of paralytic shellfish toxins by bacteria associated with Alexandrium spp. (Dinophyta) in culture. Appl Environ Microbiol (1997) 1.49
Component-resolved diagnosis of vespid venom-allergic individuals: phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization. Allergy (2012) 1.48
Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology (2000) 1.47
Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol (1997) 1.47
Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry (2001) 1.46
Schistosomiasis and the Dogon country (Mali) Am J Trop Med Hyg (1992) 1.46
Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Methods (2005) 1.45
[Strongyloidiasis and HTLV-I infection]. Med Clin (Barc) (1999) 1.44
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. J Acquir Immune Defic Syndr (1999) 1.44
The origin of the Jingwei gene and the complex modular structure of its parental gene, yellow emperor, in Drosophila melanogaster. Mol Biol Evol (2000) 1.43
Community cancer control in a rural, underserved population: the Appalachian Leadership Initiative on Cancer Project. J Health Care Poor Underserved (2001) 1.41
[Interferon in chronic hepatitis in patients infected by the human immunodeficiency virus: yes or no?]. Med Clin (Barc) (1992) 1.40
Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.40
Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J (2000) 1.40
[An esophageal ulcer due to cytomegalovirus in a female patient infected with the human immunodeficiency virus without serious immunosuppression: is this an acquired immunodeficiency syndrome?]. Med Clin (Barc) (1992) 1.40
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2000) 1.39
[Intensification of antiretroviral treatment]. Rev Clin Esp (2000) 1.39
HTLV-I and HTLV-II infections in Spain. Vox Sang (1993) 1.39
Fermi gap stabilization of an incommensurate two-dimensional superstructure. Phys Rev Lett (2005) 1.39
High triglyceride levels as a predictor of mortality in AIDS patients. AIDS (1993) 1.39
[Complications in Mediterranean boutonneuse fever: prospective study of 78 patients]. Rev Clin Esp (1989) 1.39
[Speed users (metamphetamines): a return journey between ecstasy (MDMA) and cocaine. Clinical, preventive and health-care questions]. Aten Primaria (2004) 1.39
[Antiretroviral treatment against HIV]. Med Clin (Barc) (1995) 1.39
Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status. Int J Tuberc Lung Dis (2008) 1.38
Etiology of traveller's diarrhea in Spanish travellers to developing countries. Eur J Epidemiol (1993) 1.38
Persistent pleural effusion and post-traumatic subarachnoidal-pleural fistula. Eur J Cardiothorac Surg (1991) 1.38
[Study of 164 episodes of infectious endocarditis in drug addicts: comparison of HIV positive and negative patients]. Rev Clin Esp (1994) 1.38
[Incidence of enteropathogens in patients with human immunodeficiency virus infection]. Med Clin (Barc) (1994) 1.38
[Interrelationship between the duration of HIV infection, viral load and CD4 positive lymphocyte count]. Med Clin (Barc) (1998) 1.38
Circulating hepatitis C virus genotypes in Spain. The Hepatitis/HIV Spanish Study Group. Vox Sang (1996) 1.38
[Serologic activity against retrovirus in patients with Sjögren syndrome]. Med Clin (Barc) (1993) 1.38
[Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)]. Enferm Infecc Microbiol Clin (2000) 1.38
Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol (2000) 1.35
Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients. AIDS (1999) 1.34
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses (2005) 1.34
Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr (2001) 1.33
A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS (1993) 1.33
Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes. J Virol (1995) 1.33
Measurement of triceps skinfold thickness. An investigation of sources of variation. Br J Prev Soc Med (1971) 1.31
Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. BMJ (1990) 1.30
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28